preclinical testing

AACT, Inc. is a research-and-development-stage biopharmaceutical company focused on oncology, developing small-molecule, patent-protected drugs that exploit biological differences between tumor and normal cells. Its technology derives from research at the Icahn School of Medicine at Mount Sinai and the Fels Institute for Cancer Research and Molecular Biology of Temple University School of Medicine. Lead candidates include AA150030 and AA108600. AACT also runs an antiviral program developing broad-spectrum host-directed antivirals.

drug discoverykinase inhibitor developmentmedicinal chemistrynebulized pulmonary drug delivery

AAVion is a biotechnology company developing next-generation AAV gene therapies to overcome the limitations of conventional gene delivery and expand access to genetic medicines. Its proprietary platform enables delivery and restoration of therapeutic genes that exceed the traditional AAV packaging limit. AAVion is advancing gene therapies for rare inherited cardiomyopathies and neuromuscular disorders. It was founded by Dr. Prasad Konkalmatt, an AAV gene therapy scientist.

AAV gene therapy developmentcapsid engineeringDual-AAV strategy for large gene deliverypromoter engineeringvector design

AntiRadical Therapeutics LLC is a company focused on anti-aging therapeutics addressing unmet medical needs for the aging demographic. It develops DETOPS, a drug based on stable nitroxide free radicals with antioxidant properties that mimic endogenous superoxide dismutase and may affect nitric oxide pathways, cellular signalling and vascular dynamics. DETOPS has undergone extensive preclinical testing and can be administered orally, dermally (topical), or by intramuscular injection.

anti-aging researchdrug development

CellField Technologies provides human-relevant preclinical testing for joint disease therapeutics. Its MAJIC platform delivers predictive data to de-risk osteoarthritis and rheumatoid arthritis drug development programs.

drug screeningjoint disease drug development de-risking

CX Therapeutics is a medical device company focused on developing an improved cerclage to treat cervical insufficiency and prevent preterm birth. Working with mechanical engineers and medical device experts, the company aims to make cerclage safer and more effective. Its work includes preclinical testing of a prototype medical device and benchtop testing of the Cx Device.

benchtop testingmedical device development